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Introduction
Skeletal muscle regeneration is mediated by myogenic 
cell populations that reside in the muscle and behave as 
adult stem cells [1-3]. In the present article we will focus 
on satellite cells, which represent the best characterized 
population of adult muscle stem cells. Satellite cells are a 
population of mononuclear cells that reside between the 
muscle ﬁ  ber and the basal lamina [1,4].
While satellite cells spend most of their lifetime in a 
quiescent state, upon muscle damage they can re-enter 
the cell cycle and either: undergo a symmetric cell 
division to self-renew and expand the satellite cell 
popu  lation; or undergo an asymmetric cell division that 
results in the cell on the basal lamina side maintaining 
the satellite cell identity, while the cell adjacent to the 
muscle ﬁ  ber enters the myogenic diﬀ  erentiation program 
[5,6]. Cell fate deci  sions undertaken by the satellite cells 
upon muscle damage are thought to be regulated through 
epigenetic mechanisms that modify the structure of 
chromatin without changing the DNA sequence. Th  ese 
epigenetic changes lead to altered gene expression 
proﬁ   les that contribute to deﬁ   ning cellular identity. 
Understanding the nature, origin and raison d’être of 
these epigenetic modiﬁ  cations in the regenerating muscle 
will be critical to determining how satellite cells can be 
maintained  ex vivo such that this adult stem cell 
population can be ampliﬁ  ed for therapeutic use to treat 
muscle-wasting diseases.
Polycomb group and Trithorax group proteins in 
muscle regeneration
Genetic screens for mutations that caused patterning 
defects in Drosophila led to the identiﬁ  cation  of 
Polycomb group (PcG) proteins, which act to repress 
developmentally regulated gene expression [7,8]. Further 
screening to identify genes that rescued the Polycomb 
phenotype resulted in the identiﬁ  cation of an antagonistic 
group of proteins, termed Trithorax group (TrxG) 
proteins, which act to establish high levels of trans  crip-
tion from these same developmentally regulated loci. 
Over the past 5 years, studies in human and mouse 
embry  onic stem cells have suggested that PcG and TrxG 
families of epigenetic regulators modulate pluripotency 
and lineage restriction of a number of cell types [9].
While not all PcG and TrxG proteins have been exten-
sively studied, the role of the PcG and TrxG histone 
methyl  transferases in regulating gene expression is well 
characterized. Th  ese histone methyltransferases include 
the lysine methyltransferase family 6 (KMT6) enzymes 
Ezh1 and Ezh2 that act as the active subunit of the 
polycomb repressor complex 2 (PRC2), and the TrxG 
lysine methyltransferase family 2 (KMT2) members (that 
is, MLL1, MLL2, MLL3, MLL4, hSET1A, and hSET1B) 
that act as the active subunit of Ash2L-containing methyl-
transferase complexes. Th   e KMT6 family of 
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© 2011 BioMed Central Ltdmethyl  transferases is involved in depositing the 
transcriptionally repressive mark trimethyl histone H3 at 
lysine 27 (H3K27me3) on developmentally regulated 
genes, where  as the transcrip  tionally permissive mark 
trimethy  lation of H3 at lysine 4 (H3K4me3) is mediated 
by the KMT2 family of methyltransferases. As the 
repressive H3K27me3 mark is heritably transmitted to 
daughter cells [10], and is domi  nant over H3K4me3 [11], 
the activation of transcription at developmentally 
regulated genes requires the activity of a third family of 
enzymatic proteins, which act as H3K27me3 de  methy-
lases – namely, lysine demethylase family 6 (KDM6) 
members UTX and JMJD3 [12-14]. Th   e KMT6 family of 
enzymes thus establishes gene silencing at develop-
mentally regu  lated loci, while the KDM6 and KMT2 
families of enzymes work together to antagonize this 
repressive activity and permit gene expression in speciﬁ  c 
cell types. Reciprocally, KMT6-mediated methylation of 
histones is used to silence developmentally regulated 
genes as lineage restriction takes place [15].
Several developmentally regulated, lineage-speciﬁ  c 
regu  lators have been deﬁ   ned in muscle regeneration. 
Th   ese include Pax7 in the quiescent and activated satellite 
cells, MyoD and Myf5 in the proliferating myoblasts, and 
myogenin (Myog) in the fusion-competent myocytes that 
repair the damaged ﬁ  ber (see Figure 1). While the com-
plete pathway of epigenetics that modulate the temporal 
and spatial expression of these lineage-speciﬁ  c regulators 
remains to be elucidated, strong evidence exists showing 
a role for PcG/TrxG antagonism in modulating the 
expression of these muscle-speciﬁ  c transcriptional regu-
lators at the diﬀ  erent stages of muscle regeneration.
In quiescent satellite cells, the Pax7 gene is expressed 
while modulators of cell-cycle progression and muscle-
speciﬁ   c transcriptional regulators remain silenced. To 
date, epigenetic analysis of quiescent satellite cells has 
been limited by technical challenges. Firstly, the current 
techniques for explanting muscle tissue and growing 
progenitors ex vivo are by themselves suﬃ   cient to trigger 
satellite cell diﬀ  erentiation, altering the epigenomic proﬁ  le. 
Secondly, the limited number of quiescent satellite cells 
present on a muscle ﬁ   ber [16] has to date precluded 
chromatin immunoprecipitation analysis to determine 
the role of PcG and TrxG proteins in establishing the 
epigenetic state of these cells. Th  e existence of histone 
modiﬁ  cations at developmentally regulated genes during 
the later stages of myogenesis, however, implies a regu-
lation through the antagonistic functions of PcG and 
TrxG proteins. For instance, a transition from a transcrip-
tionally permissive H3K4me3 mark to a repressive 
H3K27me3 mark induced by Ezh2 was observed on the 
Pax7 gene as proliferating myoblasts turn oﬀ   this impor-
tant marker of satellite cell identity, and prepare for 
diﬀ  erentiation [17]. Similarly, genes involved in cell-cycle 
Figure 1. Epigenetic regulation of developmentally regulated 
genes in satellite-cell-mediated muscle regeneration. Regulation 
of gene expression by Polycomb group (PcG) and Trithorax group 
(TrxG) methyltransferase complexes at developmentally regulated 
loci is depicted. Histone modifi  cations or the presence of PcG/
TrxG complexes on the gene highlighted in grey are predicted and 
have not been formally shown (please see text for rationale on the 
predictions). (a) Cells undergoing symmetrical cell division will 
express Pax7 and the genes involved in cell-cycle progression. These 
genes are predicted to be marked by TrxG-mediated H3K4me3, 
while the repressed MyoD/Myf5 and Myog genes would be marked 
by the repressive H3K27me3 mark. In the case of Myf5/MyoD, it will 
be interesting to determine whether these are bivalently marked 
genes poised for transcription. (b) During asymmetrical cell division, 
one of the two cells will go on to become a proliferating myoblast. 
The proliferating myoblast will express genes involved in cell-cycle 
progression, as well as Pax7, and Myf5/MyoD. These genes are known 
to be marked by H3K4me3 in proliferating myoblasts, and in the case 
of Myf5 it has been shown that this mark is established through the 
recruitment of TrxG proteins by Pax7. (c) In terminally diff  erentiating 
cells that will fuse to the damaged fi  ber, Pax7 is silenced along with 
genes involved in cell-cycle progression. This repression involves PcG-
mediated incorporation of H3K27me3 into the chromatin at these 
genes. At this time, the Myog gene becomes expressed as MyoD 
collaborates with Mef2d and Six4 to establish the transcriptionally 
permissive state of H3K4me3. MRF, muscle regulatory factor.
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mark in proliferation conditions [18], and then become 
enriched for the repressive H3K27me3 mark [19] through 
a process involving the E2F family of transcription factors 
and the retinoblastoma protein as the cells exit the cell 
cycle to terminally diﬀ  erentiate [20]. A role for PRC2-
mediated repression at the Myf5 locus in quiescent 
satellite cells can also be inferred from the observation 
that this gene becomes marked by the antagonizing 
TrxG-mediated mark of H3K4me3 in proliferating myo-
blasts [21]. While these ﬁ  ndings are strongly sugges  tive 
of a role for TrxG and PcG in maintaining the quiescent 
state, conﬁ  rmation of this mechanism will require the use 
of more sensitive detection techniques such as chromatin 
immunoprecipitation sequencing for H3K4me3 and 
H3K27 on satellite cells obtained by laser-capture micro-
dissection of ﬁ  xed muscle tissue.
Upon muscle injury, satellite cells become activated 
and re-enter the cell cycle. Th  ese cells begin to express 
cell-cycle regulatory genes, which become marked by 
H3K4me3 [18]. Satellite cells that divide in the planar 
orientation along the ﬁ  ber will undergo a symmetrical 
cell division and give rise to two satellite cells that can re-
enter the quiescent state [5]. In contrast, cells that divide 
in the apical–basal plane will undergo asymmetric cell 
division to give rise to one satellite cell (which returns to 
the quiescent state), and one proliferating myoblast [5]. 
Th   e proliferating myoblast is characterized by the 
expression of Myf5/MyoD [5] as well as genes that regu-
late cell-cycle progression while the satellite cell marker 
Pax7 is progressively silenced. As described above, the 
activation of transcription at Myf5 and genes involved in 
cell-cycle progression coincides with enrichment of the 
transcriptionally permissive H3K4me3 mark within their 
chromatin [21]. In contrast, the Pax7 gene transitions 
from a transcriptionally permissive state of H3K4me3 to 
a repressive state of H3K27me3 as the cell proceeds 
through diﬀ  erentiation [17].
Th   e formation of multinucleated myotubes requires the 
downregulation of Pax7, Myf5, and cell-cycle regulatory 
genes, and the activation of Myog. Expression of the 
Myog gene coincides with the removal of the repressive 
H3K27me3 mark [22,23] and the appearance of the 
transcriptionally permissive H3K4me3 mark within the 5’ 
end of the gene [23,24]. Coincident with the terminal 
diﬀ  erentiation, myoblasts exit the cell cycle as regulators 
of this process are silenced through incorporation of the 
H3K27me3 modiﬁ  cation into chromatin marking their 
respective genes [19]. While our knowledge of epigenetic 
marking of chromatin in proliferating and diﬀ  erentiating 
myoblasts is currently restricted to a limited number of 
genes, advances in high-throughput sequencing should 
soon provide the epigenetic status for the entire muscle 
transcriptome at diﬀ  erent stages of muscle regeneration.
Targeting Polycomb group and Trithorax group 
proteins to muscle-specifi  c genes
Th  e H3K27me3 mark is established by proteins of the 
KMT6 (Ezh1 and Ezh2) family of PcG proteins. In 2004, 
Caretti and colleagues were the ﬁ  rst to demonstrate the 
involvement of PcG proteins in myogenic gene silencing 
[25]. Th  ey showed that the expression of two terminal 
muscle diﬀ   erentiation genes, Myh10 (myosin, heavy 
polypeptide 10, nonmuscle) and Ckm (muscle creatine 
kinase), are silenced via PcG repression in proliferating 
myoblasts, and that this silencing is lifted upon diﬀ  eren-
tiation. An interesting aspect of these ﬁ  ndings is that the 
recruitment of Ezh2 (KMT6B), the catalytic subunit of 
PRC2, to its target genes in precursor cells is mediated by 
the sequence-speciﬁ   c transcription factor YY1. Th  e 
mechanism that allows YY1-mediated targeting of Ezh2 
to these muscle-speciﬁ   c genes is intriguing, as both 
proteins are ubiquitously expressed. Furthermore, as 
hundreds of genes are coordinately induced upon 
myogenic diﬀ  erentiation [26-29], it will be important to 
identify those genes that are silenced by PRC2 in 
precursor cells, and to determine whether YY1 mediates 
KMT6 recruitment in all such instances.
Studies of the Ezh2-mediated repression of Notch1 
expression in TNFα-treated satellite cells did not examine 
the mechanism of PRC2 recruitment [30]. Studies of the 
Pax7 gene, however, showed that YY1 also mediates the 
recruitment of Ezh2 to the transcriptional regulatory 
region of this marker of satellite cell identity to silence its 
expression in proliferating myoblasts [17]. Th  is recruit-
ment of Ezh2 to the Pax7 gene is modulated through 
mitogen-activated protein kinase (MAPK) signaling, 
where Ezh2 is phosphorylated by p38 MAPK to permit 
its interaction with the enhancer bound YY1. In contrast, 
recruitment of Ezh2 by YY1 to the Myh10 gene is not 
modulated by p38 MAPK signaling [17]. Furthermore, 
Ezh2 departs the Myh10 and CKm genes when p38 
MAPK signaling is activated upon terminal diﬀ  eren-
tiation [25]. An impor  tant question raised by these 
studies, therefore, is how p38 MAPK can stimulate YY1 
and Ezh2 recruitment to a given locus (Pax7, silenced in 
diﬀ  erentiated cells) but not to another (Myh10, silenced 
in proliferating cells). Possibly the com  position of 
multiprotein complexes at the regulatory region of these 
genes is not entirely deﬁ  ned, and p38-mediated stimu-
lation depends on additional unidentiﬁ   ed factors that 
might be diﬀ  erentially recruited to these loci.
Evidence suggests a role for additional factors in 
targeting Ezh2 to speciﬁ   c loci since high-throughput 
studies in embryonic stem cells show that the genomic 
binding proﬁ  les of PRC2 and YY1 do not overlap [31]. In 
these pluripotent cells, the histone demethylase Jarid2 
has been shown to mediate recruitment of PRC2 (Ezh2) 
to speciﬁ  c genes [32-34]. Jarid2 could also be involved in 
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in satellite cells before being downregulated twofold 
during diﬀ  erentiation (FJD and AB, unpublished obser-
va  tions based on published datasets [35,36]) Determining 
the relative role of these two pathways to the establish-
ment of PRC2-mediated transcription repression during 
muscle regeneration will be of future interest, and will 
require satellite cell-speciﬁ   c knockout/knockdown of 
YY1 and/or Jarid2.
An important implication of the ﬁ   ndings on gene 
repression mediated by PRC2 is that this silencing of 
muscle development genes must be lifted for diﬀ  eren-
tiation to occur. Removal of the H3K27me3 mark is 
mediated by KDM6 family members UTX (KDM6A) and 
JMJD3 (KDM6B) [12-14]. Interestingly, the demethylase 
UTX can associate with TrxG proteins, which antagonize 
PcG function by marking genes for activation [37]. To 
date, the recruitment of KDM6 family members to 
muscle-speciﬁ   c genes has only been examined in 
terminally diﬀ  erentiating myoblasts. In these cells, UTX 
is ﬁ   rst recruited to the promoter region of the Myog 
gene, where it then associates with the elongating RNA 
polymerase II to demethylate a region extending over the 
entire length of the gene [22,23]. Interestingly, recruit-
ment of the UTX demethylase to the Myog locus is 
mediated by the homeodomain transcription factor Six4 
[22,23]. Importantly, Six1 and Six4 factors are involved in 
upregulating the expression of Pax3, MyoD, Myf5 and 
Myog [38-40] and of fast-twitch muscle-function genes 
[41] during muscle development. Furthermore, Six1 and 
Six4 are essential for terminal diﬀ   erentiation in adult 
myoblasts [38,42] and they function in part by 
cooperating with the muscle regulatory factors (MRFs) 
MyoD and Myog in activating target gene transcription 
[42]. Genome-wide proﬁ  ling of Six1 binding in myoblasts 
revealed a strong correlation between Six binding and 
target gene activation during diﬀ   erentiation [42]. Th  is 
observation suggests that Six factors may have a global 
function in recruiting UTX complexes to develop-
mentally regulated genes during myoblast diﬀ  er  entiation.
Following removal of the repressive H3K27me3 modiﬁ  -
ca  tion, developmentally regulated genes become enriched 
for the transcriptionally permissive H3K4me3 mark to 
establish high levels of gene expression. Indeed, studies 
in proliferating myoblasts have shown that Pax7 is 
responsible for recruitment of the TrxG complex Ash2L 
into the Myf5 locus to mark the gene by H3K4me3 [21]. 
In terminally diﬀ  erentiating myoblasts, targeting of the 
Ash2L complex to the Myog promoter is mediated by the 
MADS-domain transcription factor Mef2d [23,24]. 
Several diﬀ  erent transactivators can thus clearly recruit 
Ash2L complexes to developmentally regulated genes to 
mediate the marking of chromatin by H3K4me3 during 
muscle regeneration. Importantly, the recruitment of 
Ash2L to the Myog gene has been shown to be modulated 
by p38 MAPK signaling through a direct phosphorylation 
of Mef2d [23,24]. Th   is ability to modulate the recruitment 
of Ash2L to the Myog promoter through inhibition of 
p38 MAPK signaling suggests a possible mechanism to 
regulate gene expression therapeutically.
DNA methylation in muscle regeneration
In addition to the repressive H3K27me3 mark mediated 
by PRC2/Ezh2 [10], methylation of CpG dinucleotides 
(5-methylcytosine) within a gene regulatory region can 
be heritably transmitted to daughter cells to block trans-
cription [43,44]. Th  e importance of this methylation of 
DNA in myogenesis has been established from early 
studies showing that treatment of ﬁ   broblast with the 
inhi  bitor of DNA methylation (5-azacytidine) caused 
cells to diﬀ   erentiate towards the muscle lineage [45]. 
Subse  quently, the Weintraub group used a genomic 
library obtained from 5-azacytidine-treated ﬁ  broblasts to 
clone the master regulator of muscle gene expression, 
MyoD [46].
Reciprocally, more recent studies have shown that 
treatment of C2C12 cells with an inhibitor of DNA methy-
lation (zebularine) caused the cells to diﬀ  erentiate into a 
smooth muscle lineage [47]. Th  is observation provides 
strong evidence that DNA methylation plays an important 
role in repressing factors involved in estab  lishing alternate 
cell fates. Interestingly, the two repres  sive marks of CpG 
methylation and H3K27me3 have been shown to co-exist 
at speciﬁ   c genes in cells of restricted/limited potency 
[9,48]. Moreover, co-existence of methylated H3K27 and 
CpG dinucleotides within transcriptional regulatory 
regions is not coincidental because Ezh2 has been shown 
to target the de novo DNA methyltransferase enzymes 
DNMT3a and DNMT3b to speciﬁ   c genes [49]. Th  is 
combination of epigenetic marks is proposed to provide a 
more stable repression of trans  cription at genes coding for 
either mediators of pluri  potency or determination factors 
that are speciﬁ  c to alternate cell lineages [9,48]. Not all 
Ezh2 target genes, however, are marked by methylated 
CpG dinucleotides. Instead, genes with nonmethylated 
CpG dinucleotides are repressed through a bivalent 
chromatin state of nucleosomes doubly marked by 
methylated H3K4 and H3K27 that remain poised for 
activation [50]. Th   e presence of methy  lated H3K4 within 
the nucleosome is proposed to block the recruitment of 
DNTM3a/DNTM3b to chromatin [51,52] and to maintain 
the ability of these PcG marked genes to be activated later 
in lineage commitment. As a general rule, therefore, genes 
no longer required for lineage progres  sion would be 
targeted for stable repression by a combi  nation of 
H3K27me3 and CpG methylation, while genes required 
for further lineage progression would be bivalently marked 
by H3K4me3 and H3K27me3.
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regulating expression of muscle-speciﬁ  c genes remains to 
be established. Th  e ﬁ   nding that methyl-CpG binding 
proteins mediate reorganization of chromatin during 
terminal myogenesis, however, conﬁ  rms an essential role 
for this epigenetic mark in muscle regeneration [53]. 
Recent studies have shown the involvement of Ezh2 and 
DNMT3b in establishing repression at the Notch-1 pro-
moter during satellite cell activation [30]. Indeed, down-
regulation of Notch-1 occurs in an Ezh2-dependent 
manner and results in accumulation of the repressive 
H3K27me3 mark as well as recruitment of DNMT3b to 
mediate DNA methylation within the promoter region of 
this gene [30]. It remains to be determined whether Ezh2 
or DNMT3b plays a role in downregulating other media-
tors of satellite cell function such as Pax7 in proliferating 
myoblasts. Over  laying genome-wide DNA methylation 
(obtained using either bisulﬁ   te sequencing or MeDIP) 
and H3K27me3 patterns (obtained using chromatin 
immuno  preci  pitation) in satellite cells will permit a full 
appreciation of the extent to which these complementary 
epigenetic marks modulate the myogenic gene expression 
program.
The function of Pax7 in satellite cells
Mice deﬁ  cient in Pax7 expression are characterized by 
low-weight, skeletal muscle of small caliber and by null 
or very low numbers of satellite cells [54]. Surprisingly, it 
was recently reported in adult mice that myogenic 
regeneration occurs in the absence of Pax7 (and/or Pax3), 
suggesting that the homeodomain transcription factor 
would only be essential for growth and regeneration 
during the juvenile period [55]. However, considering the 
role of Pax7 in establishing the H3K4me3 marks at 
muscle regulatory genes such as Myf5 [21], an important 
role for Pax7 in the epigenetic modiﬁ  cation of histones in 
adult satellite cells is likely to exist.
In light of the fact that satellite cells can regenerate 
damaged muscle in the absence of Pax7, we propose that 
this transcriptional regulator could act prior to the onset 
of adulthood to establish stable epigenetic modiﬁ  cation 
of chromatin whose inﬂ   uence on gene expression 
continues after its expression has been ablated. Th  is  idea 
of epigenetic marking of chromatin to maintain cellular 
memory is supported by studies in Myf5-Cre/ROSA26-
YFP mice, where it was shown that YFP+ satellite cells 
(which had previously expressed Myf5 and represent 90% 
of the satellite cell population) turn on expression of the 
endogenous Myf5 gene with faster kinetics than YFP– 
satellite cells [5]. Consistent with this, we propose a 
model in which Pax7-dependent epigenetic marks set up 
during the juvenile growth phase would establish satellite 
cell identity permanently. As these epigenetic marks 
could persist over successive cycles of proliferation/
quiescence in satellite cells, such a scenario would make 
Pax7 expression dispensable in adult cells. However, the 
identiﬁ   cation of Pax7-dependent marks in juvenile 
satellite cells, and of Pax7-bound genomic loci, will be 
required to verify this hypothesis formally.
How might Pax7 act to epigenetically mark genes of the 
muscle transcriptome? Pax7 could participate in the 
establishment of a bivalent state at muscle genes (such as 
Myf5) in quiescent satellite cells where the H3K4me3 
mark co-exists with the repressive H3K27me3 mark to 
poise them for activation [50]. In such a case, activation 
of the muscle genes would no longer require Pax7 in the 
adult satellite cells as the chromatin would already be 
marked by H3K4me3 in juvenile satellite cells. Th  is  mark 
would persist through rounds of proliferation/quiescence, 
but would be counteracted at speciﬁ  c genes (depending 
on cellular context) by the regulated removal of the 
H3K27me3 mark. Recruitment of a KDM6 family histone 
demethylase speciﬁ   c to the gene by an additional 
transcription factor such as Six4 would thus be suﬃ   cient 
to establish expression of muscle development genes.
Alternatively, Pax7 could epigenetically mark genes of 
the muscle transcriptome through the introduction of 
variant histones within its target genes. Previous studies 
have shown that Pax7 can interact with HIRA, a 
chaperone speciﬁ   c for the variant histone H3.3 [56]. 
Because nucleosomes enriched in histone H3.3 are 
generally found at the start sites of transcribed genes [57] 
and are involved in epigenetic memory [58], the Pax7–
HIRA interaction could prevent the permanent silencing 
of its target genes by marking them with H3.3. Indeed, 
the MyoD gene is marked by H3.3 in proliferating 
myoblasts [59]. Interestingly, this mark is stable enough 
to permit expression of MyoD in Xenopus oocytes that 
have undergone nuclear transfer using a nucleus from a 
muscle donor cell [58]. Th  ese two scenarios, which are 
not mutually exclusive, could explain how Pax7 would 
establish the inheritance of an active chromatin state at 
important loci in juvenile satellite cells, prior to their 
transcriptional activation.
Modulating epigenetics as a therapeutic approach 
to muscular dystrophy
Th   e importance of the epigenetic pathways in modulation 
of tissue-speciﬁ  c gene expression makes them excellent 
candidate targets for disease interventions. Several drugs 
that attempt to modify epigenetic mechanisms are 
currently undergoing clinical trial [60,61]. Th  ese  include 
histone deacetylase inhibitors [61], histone methyltrans-
ferase inhibitors [62], as well as the inhibitor of DNA 
methylation 5-azacytidine [63].
In the case of muscular dystrophy, histone deacetylase 
inhibitors are currently being examined using the mdx 
mouse model for their ability to improve the dystrophic 
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inhibi  tors prevent the eﬀ  ects of disrupted nitric oxide 
signaling on acetylation at chromatin within the diseased 
muscle [65]. Th  e eﬀ   ects of prolonged treatment with 
drugs that inhibit these ubiquitously required chromatin-
modifying enzymes, however, are of potential concern. 
As an alternative or complement to this strategy, the 
identiﬁ  cation of small molecules that promote or disrupt 
the speciﬁ   c protein–protein interactions required for 
targeting the epigenetic enzymes to determined loci 
within the genome could have a similar beneﬁ  t without 
the side eﬀ  ect of modifying gene expression in other cell 
types. Along this line of thought, a cell-permeable small 
molecule that inhibits the protein–protein interaction 
between bromo  domain-containing protein BRD4 and 
histones H3-acetylated at lysine 14 has recently been 
reported [66]. Th   e broad-reaching eﬀ  ects of blocking this 
inter  action, however, maintain the same caveats 
described above for blocking the enzymatic activity of 
ubiquitously expressed epigenetic proteins.
Future screens should be directed at disrupting the 
interactions between the PcG and TrxG proteins and the 
transcriptional regulators that target these enzymes to 
muscle-speciﬁ  c genes. As many of the PcG and TrxG 
activities are present in multiprotein complexes, the 
screening of molecules to disrupt this targeted recruit-
ment to muscle-speciﬁ   c genes will ﬁ   rst require the 
delineation of speciﬁ  c subunits that mediate direct inter-
actions with the transcriptional regulator of interest. Th  e 
use of small molecules to disrupt interactions between 
transcriptional regulators and PcG and Trx proteins will 
thus require extensive research before they can be 
developed to treat muscular dystrophy.
An alternative approach to targeting PcG and TrxG 
activities to speciﬁ  c genes is the use of artiﬁ  cial zinc-
ﬁ   nger transcription factors [67]. Th  is technique has 
recently been used to target the VP16 transactivation 
domain to a 9-base-pair sequence within the utrophin 
promoter, allowing for an upregulation of expression 
from the endogenous gene in the mdx mouse [68]. In this 
case, a three-zinc-ﬁ   nger array fused to VP16 was 
expressed in transgenic animals using the muscle-speciﬁ  c 
myosin light-chain promoter. While a 9-base-pair target 
sequence is not suﬃ     cient to ensure a single genomic 
targeting event, artiﬁ  cial activators have been generated 
containing six zinc ﬁ  ngers that permit the targeting of a 
transactivation domain to an 18-base-pair sequence of 
the γ-globin gene that is unique in the genome [69]. As 
an alternative to the VP16 fusion with the gene-speciﬁ  c 
zinc ﬁ  nger array, an enzyme such as Ezh2, UTX, or MLL1 
could be fused to these artiﬁ  cial DNA binding domains. 
In this way, TrxG or PcG fusion proteins could be 
targeted to individual loci within the genome to mediate 
silencing or activation of speciﬁ  c genes.
While utrophin is a therapeutically important gene for 
treatment of muscular dystrophy, an alternative target 
has been suggested by the recent ﬁ  nding that the discre-
pancy between the mild dystrophic phenotype observed 
in mdx mice and the severe phenotype observed in 
humans can be explained through the inactivation of the 
telomerase in the latter [70]. An artiﬁ  cial transcriptional 
zinc-ﬁ  nger-mediated upregulation of telomerase activity 
through epigenetic mechanisms speciﬁ   cally in satellite 
cells could perhaps lead to increased self-renewal such 
that the stem cells do not become depleted as the need 
for repair continues over the lifetime of the patient. A 
similar approach has recently been explored to repress 
expression of telomerase in transformed cells using 
artiﬁ   cial zinc ﬁ   ngers fused to the transcriptional 
repressor domain of KRAB [71].  Epigenetic enzymes 
could thus represent a viable target for future gene 
therapies to permit muscle repair in muscular dystrophy 
patients. However, current limitations associated with 
gene therapy remain – we must ensure that these zinc 
ﬁ   nger proteins are targeted to muscle cells eﬃ   ciently 
while also ensuring that they do not activate muscle 
genes in other cell types.
Conclusions
Th   ere is little doubt that the incredible ability of certain 
structural features of chromatin to be perpetuated over 
several cell divisions is at play in controlling the fate of 
adult muscle stem cells. Th  e elucidation of epigenetic 
mechanisms regulating the function of satellite cell 
function is still just beginning, but signiﬁ  cant progress is 
being made at an exponential pace, thanks in part to our 
increasing knowledge of how these molecular pathways 
are laid out in embryonic stem cells. Moreover, technical 
advances are constantly emerging, speeding up our study 
of the inner workings of the epigenetic control machinery 
and helping with the design of new therapeutic 
approaches based on this knowledge. While most 
muscular illnesses are not epigenetic diseases per se, we 
can envision a near future where epigenetic therapies will 
be part of a successful treatment regimen for dystrophic 
patients.
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